Charles River Laboratories Announces Third-Quarter 2022 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Charles River Laboratories (CRL) Announces Avian Vaccine Divestiture
November 2, 2022 7:21 AM EDTCharles River Laboratories (NYSE: CRL) announced that it has signed a definitive agreement to divest its Avian Vaccine business for approximately $170 million in cash with potential contingent payments of up to an additional $30 million, subject to certain closing adjustments.
The Avian... More
Charles River Laboratories (CRL) Tops Q3 EPS by 9c, Offers Guidance
November 2, 2022 7:06 AM EDTCharles River Laboratories (NYSE: CRL) reported Q3 EPS of $2.63, $0.09 better than the analyst estimate of $2.54. Revenue for the quarter came in at $989.2 million versus the consensus estimate of $974.65 million.
GUIDANCE:
Charles River Laboratories sees FY2022 EPS of $10.80-$10.95, versus the consensus of... More
